Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity.
Health economic aspects are crucial in arguing the feasibility of setting up a new service using an unlicensed treatment. Overall, the costs of intradetrusor botulinum neurotoxin-A treatment appear to be modest relative to the improvement in quality of life. However, in managing the overactive bladder, there is a need for a widely accepted definition of 'clinical improvement' or a common outcome measure to direct future clinical and health economic research.
Sangster
Philippa
P
Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Kalsi
Vinay
V
D000283:Administration, Intravesical; D019274:Botulinum Toxins, Type A / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D006801:Humans; D009465:Neuromuscular Agents / Q000191:economics* / Q000627:therapeutic use; D011788:Quality of Life; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000191:economics
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A